Harmony Biosciences(US:HRMY)2025-11-04 13:05Financial Performance - WAKIX franchise generated net revenue of approximately $239 million in Q3 2025, representing a 29% year-over-year revenue growth[2] - The company raised its 2025 revenue guidance to a range of $845-$865 million from the previous range of $820-$860 million[2] - Harmony Biosciences will report full Q3 2025 financial results on November 4th, 2025, before the U.S. financial markets open[2] - The preliminary results are based on management's initial review and are subject to revision, indicating potential changes in actual results[4] Product Performance and Market Potential - The average number of patients increased by approximately 500, reaching 8,100 average patients in Q3 2025, indicating a strong trajectory towards potential blockbuster status for WAKIX in narcolepsy[2] - WAKIX is approved for treating excessive daytime sleepiness and cataplexy in adult and pediatric patients with narcolepsy, showcasing its therapeutic potential[5] - The company is exploring the therapeutic potential of pitolisant in additional indications, which may enhance its market position[24] Strategic Focus and Development - Harmony is committed to developing innovative therapies for patients with rare neurological diseases, reflecting its strategic focus[21] - The company emphasizes the importance of favorable insurance coverage and reimbursement for WAKIX to support its commercialization efforts[24] - Harmony's growth strategy includes identifying and integrating additional products or candidates with significant commercial potential[24]